At a glance

Sequence database
This dataset include 18,708 unique individuals.
Regions covered
pol (PR/RT and integrase)
Sensitivity analyses to evaluate number of individuals by minimum
sequencing length.
PR/RT
Sensitivity analyses to evaluate number of individuals by minimum
sequencing length.
Demographics
Below I am showing the data from the 13538 participants with a
minimum length og 500 bp PR/RT covering PR/RT.
| Characteristic |
N = 13,538 |
| sex |
|
| Female |
4,034 (30%) |
| Male |
9,392 (69%) |
| Transgender F/M |
2 (<0.1%) |
| Transgender M/F |
110 (0.8%) |
| Age |
51 (40, 59) |
| Age group |
|
| <15 |
0 (0%) |
| ≥15-<25 |
351 (2.6%) |
| ≥25-<35 |
1,699 (13%) |
| ≥35-<45 |
2,759 (20%) |
| ≥45-<55 |
3,402 (25%) |
| ≥55-<80 |
5,154 (38%) |
| ≥80 |
173 (1.3%) |
| WHO region (origin) |
|
| WHO Africa |
2,445 (20%) |
| WHO Americas |
725 (5.9%) |
| WHO Eastern Mediterranean |
283 (2.3%) |
| WHO Europe |
8,684 (71%) |
| WHO South-East Asia |
43 (0.4%) |
| WHO Western Pacific |
72 (0.6%) |
| Regions francaises |
|
| Auvergne-Rhône-Alpes |
303 (2.2%) |
| Bourgogne-Franche-Comté |
18 (0.1%) |
| Bretagne |
1,256 (9.3%) |
| Centre-Val de Loire |
26 (0.2%) |
| Corse |
34 (0.3%) |
| Grand Est |
12 (<0.1%) |
| Guadeloupe |
645 (4.8%) |
| Guyane française |
8 (<0.1%) |
| Hauts-de-France |
29 (0.2%) |
| Île-de-France |
160 (1.2%) |
| Martinique |
922 (6.8%) |
| Mayotte |
1 (<0.1%) |
| Normandie |
690 (5.1%) |
| Nouvelle-Aquitaine |
154 (1.1%) |
| Occitanie |
3,626 (27%) |
| Pays de la Loire |
2,863 (21%) |
| Provence-Alpes-Côte-d'Azur |
2,787 (21%) |
| Réunion |
4 (<0.1%) |
| HIV stage |
|
| A |
8 (<0.1%) |
| A0 |
31 (0.2%) |
| A1 |
1,650 (12%) |
| A2 |
4,521 (33%) |
| A3 |
2,526 (19%) |
| B |
2 (<0.1%) |
| B0 |
20 (0.1%) |
| B1 |
102 (0.8%) |
| B2 |
608 (4.5%) |
| B3 |
909 (6.7%) |
| C |
35 (0.3%) |
| C0 |
10 (<0.1%) |
| C1 |
65 (0.5%) |
| C2 |
429 (3.2%) |
| C3 |
2,622 (19%) |
| Primo-infection |
|
| Non |
12,295 (91%) |
| Oui |
1,243 (9.2%) |
| Transmission risk |
|
| Bisexual |
737 (5.4%) |
| Blood |
237 (1.8%) |
| Heterosexual |
5,786 (43%) |
| IDU |
887 (6.6%) |
| Mother to child transmission |
221 (1.6%) |
| MSM |
5,028 (37%) |
| Others |
81 (0.6%) |
| Unknown |
561 (4.1%) |
| Drug use |
|
| Current |
1,228 (10%) |
| None |
6,765 (56%) |
| Past |
1,310 (11%) |
| Sometimes |
575 (4.7%) |
| Substitution |
180 (1.5%) |
| Unknown |
2,118 (17%) |
| Baseline HIV RNA level (log10) |
4.80 (4.11, 5.44) |
| Baseline CD4 count |
380 (203, 572) |
Geospatial distribution
All territories with background
All territories without background
France (mainland)

Global Network analyses
Cluster start date is defined as join date when the 3rd participant
joins clusters. Not terribly important in our analysis, more important
in time-to-event analyses.
\[
NormalizedClusterGrowth_{PastYear} =
\frac{{ClusterGrowth}_{PastYear}}{\sqrt{ClusterSize}_{PastYear}}
\]
To account for the size of the cluster, I normalized cluster growth
by the square root of cluster size. For example, the cluster size for a
given cluster in the past year is the size of the cluster at the
beginning of the year, before any any have been added.
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 2,295/13,538, i.e. 17%.

Cluster size and composition
Demographics by clustering status
| Characteristic |
Overall, N = 13,538 |
Clusters size ≥3, N = 1,363 |
Singletons, N = 12,175 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
4,034 (30%) |
107 (7.9%) |
3,927 (32%) |
|
| Male |
9,392 (69%) |
1,247 (91%) |
8,145 (67%) |
|
| Transgender F/M |
2 (<0.1%) |
0 (0%) |
2 (<0.1%) |
|
| Transgender M/F |
110 (0.8%) |
9 (0.7%) |
101 (0.8%) |
|
| Age |
51 (40, 59) |
42 (33, 53) |
51 (41, 60) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
351 (2.6%) |
68 (5.0%) |
283 (2.3%) |
|
| ≥25-<35 |
1,699 (13%) |
313 (23%) |
1,386 (11%) |
|
| ≥35-<45 |
2,759 (20%) |
377 (28%) |
2,382 (20%) |
|
| ≥45-<55 |
3,402 (25%) |
322 (24%) |
3,080 (25%) |
|
| ≥55-<80 |
5,154 (38%) |
275 (20%) |
4,879 (40%) |
|
| ≥80 |
173 (1.3%) |
8 (0.6%) |
165 (1.4%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
2,445 (20%) |
61 (4.8%) |
2,384 (22%) |
|
| WHO Americas |
725 (5.9%) |
33 (2.6%) |
692 (6.3%) |
|
| WHO Eastern Mediterranean |
283 (2.3%) |
20 (1.6%) |
263 (2.4%) |
|
| WHO Europe |
8,684 (71%) |
1,150 (91%) |
7,534 (69%) |
|
| WHO South-East Asia |
43 (0.4%) |
1 (<0.1%) |
42 (0.4%) |
|
| WHO Western Pacific |
72 (0.6%) |
2 (0.2%) |
70 (0.6%) |
|
| Regions francaises |
|
|
|
|
| Auvergne-Rhône-Alpes |
303 (2.2%) |
23 (1.7%) |
280 (2.3%) |
|
| Bourgogne-Franche-Comté |
18 (0.1%) |
3 (0.2%) |
15 (0.1%) |
|
| Bretagne |
1,256 (9.3%) |
102 (7.5%) |
1,154 (9.5%) |
|
| Centre-Val de Loire |
26 (0.2%) |
4 (0.3%) |
22 (0.2%) |
|
| Corse |
34 (0.3%) |
2 (0.1%) |
32 (0.3%) |
|
| Grand Est |
12 (<0.1%) |
0 (0%) |
12 (<0.1%) |
|
| Guadeloupe |
645 (4.8%) |
47 (3.4%) |
598 (4.9%) |
|
| Guyane française |
8 (<0.1%) |
0 (0%) |
8 (<0.1%) |
|
| Hauts-de-France |
29 (0.2%) |
3 (0.2%) |
26 (0.2%) |
|
| Île-de-France |
160 (1.2%) |
12 (0.9%) |
148 (1.2%) |
|
| Martinique |
922 (6.8%) |
99 (7.3%) |
823 (6.8%) |
|
| Mayotte |
1 (<0.1%) |
0 (0%) |
1 (<0.1%) |
|
| Normandie |
690 (5.1%) |
53 (3.9%) |
637 (5.2%) |
|
| Nouvelle-Aquitaine |
154 (1.1%) |
24 (1.8%) |
130 (1.1%) |
|
| Occitanie |
3,626 (27%) |
428 (31%) |
3,198 (26%) |
|
| Pays de la Loire |
2,863 (21%) |
260 (19%) |
2,603 (21%) |
|
| Provence-Alpes-Côte-d'Azur |
2,787 (21%) |
302 (22%) |
2,485 (20%) |
|
| Réunion |
4 (<0.1%) |
1 (<0.1%) |
3 (<0.1%) |
|
| HIV stage |
|
|
|
|
| A |
8 (<0.1%) |
3 (0.2%) |
5 (<0.1%) |
|
| A0 |
31 (0.2%) |
4 (0.3%) |
27 (0.2%) |
|
| A1 |
1,650 (12%) |
328 (24%) |
1,322 (11%) |
|
| A2 |
4,521 (33%) |
646 (47%) |
3,875 (32%) |
|
| A3 |
2,526 (19%) |
177 (13%) |
2,349 (19%) |
|
| B |
2 (<0.1%) |
0 (0%) |
2 (<0.1%) |
|
| B0 |
20 (0.1%) |
1 (<0.1%) |
19 (0.2%) |
|
| B1 |
102 (0.8%) |
13 (1.0%) |
89 (0.7%) |
|
| B2 |
608 (4.5%) |
40 (2.9%) |
568 (4.7%) |
|
| B3 |
909 (6.7%) |
30 (2.2%) |
879 (7.2%) |
|
| C |
35 (0.3%) |
2 (0.1%) |
33 (0.3%) |
|
| C0 |
10 (<0.1%) |
0 (0%) |
10 (<0.1%) |
|
| C1 |
65 (0.5%) |
5 (0.4%) |
60 (0.5%) |
|
| C2 |
429 (3.2%) |
22 (1.6%) |
407 (3.3%) |
|
| C3 |
2,622 (19%) |
92 (6.7%) |
2,530 (21%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
12,295 (91%) |
1,042 (76%) |
11,253 (92%) |
|
| Oui |
1,243 (9.2%) |
321 (24%) |
922 (7.6%) |
|
| Transmission risk |
|
|
|
<0.001 |
| Bisexual |
737 (5.4%) |
113 (8.3%) |
624 (5.1%) |
|
| Blood |
237 (1.8%) |
12 (0.9%) |
225 (1.8%) |
|
| Heterosexual |
5,786 (43%) |
249 (18%) |
5,537 (45%) |
|
| IDU |
887 (6.6%) |
36 (2.6%) |
851 (7.0%) |
|
| Mother to child transmission |
221 (1.6%) |
1 (<0.1%) |
220 (1.8%) |
|
| MSM |
5,028 (37%) |
918 (67%) |
4,110 (34%) |
|
| Others |
81 (0.6%) |
5 (0.4%) |
76 (0.6%) |
|
| Unknown |
561 (4.1%) |
29 (2.1%) |
532 (4.4%) |
|
| Drug use |
|
|
|
<0.001 |
| Current |
1,228 (10%) |
221 (18%) |
1,007 (9.2%) |
|
| None |
6,765 (56%) |
616 (49%) |
6,149 (56%) |
|
| Past |
1,310 (11%) |
135 (11%) |
1,175 (11%) |
|
| Sometimes |
575 (4.7%) |
113 (9.0%) |
462 (4.2%) |
|
| Substitution |
180 (1.5%) |
9 (0.7%) |
171 (1.6%) |
|
| Unknown |
2,118 (17%) |
162 (13%) |
1,956 (18%) |
|
| Baseline HIV RNA level (log10) |
4.80 (4.11, 5.44) |
4.95 (4.35, 5.64) |
4.78 (4.07, 5.42) |
<0.001 |
| Baseline CD4 count |
380 (203, 572) |
475 (324, 651) |
362 (180, 556) |
<0.001 |
Network analyses by region
Pays de la Loire
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 260/2,863, i.e. 9%.

Cluster size and composition
Demographics by clustering status
| Characteristic |
Overall, N = 2,863 |
Clusters size ≥3, N = 260 |
Singletons, N = 2,603 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
965 (34%) |
27 (10%) |
938 (36%) |
|
| Male |
1,887 (66%) |
232 (89%) |
1,655 (64%) |
|
| Transgender M/F |
11 (0.4%) |
1 (0.4%) |
10 (0.4%) |
|
| Age |
51 (41, 60) |
47 (38, 56) |
51 (41, 60) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
55 (1.9%) |
3 (1.2%) |
52 (2.0%) |
|
| ≥25-<35 |
333 (12%) |
44 (17%) |
289 (11%) |
|
| ≥35-<45 |
572 (20%) |
65 (25%) |
507 (19%) |
|
| ≥45-<55 |
744 (26%) |
74 (28%) |
670 (26%) |
|
| ≥55-<80 |
1,131 (40%) |
71 (27%) |
1,060 (41%) |
|
| ≥80 |
28 (1.0%) |
3 (1.2%) |
25 (1.0%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
829 (30%) |
15 (5.8%) |
814 (32%) |
|
| WHO Americas |
69 (2.5%) |
4 (1.5%) |
65 (2.6%) |
|
| WHO Eastern Mediterranean |
56 (2.0%) |
2 (0.8%) |
54 (2.1%) |
|
| WHO Europe |
1,821 (65%) |
237 (91%) |
1,584 (62%) |
|
| WHO South-East Asia |
11 (0.4%) |
0 (0%) |
11 (0.4%) |
|
| WHO Western Pacific |
22 (0.8%) |
2 (0.8%) |
20 (0.8%) |
|
| HIV stage |
|
|
|
|
| A |
1 (<0.1%) |
1 (0.4%) |
0 (0%) |
|
| A0 |
4 (0.1%) |
0 (0%) |
4 (0.2%) |
|
| A1 |
267 (9.3%) |
39 (15%) |
228 (8.8%) |
|
| A2 |
993 (35%) |
127 (49%) |
866 (33%) |
|
| A3 |
624 (22%) |
45 (17%) |
579 (22%) |
|
| B0 |
3 (0.1%) |
0 (0%) |
3 (0.1%) |
|
| B1 |
11 (0.4%) |
1 (0.4%) |
10 (0.4%) |
|
| B2 |
151 (5.3%) |
11 (4.2%) |
140 (5.4%) |
|
| B3 |
204 (7.1%) |
9 (3.5%) |
195 (7.5%) |
|
| C |
6 (0.2%) |
0 (0%) |
6 (0.2%) |
|
| C0 |
1 (<0.1%) |
0 (0%) |
1 (<0.1%) |
|
| C1 |
12 (0.4%) |
0 (0%) |
12 (0.5%) |
|
| C2 |
90 (3.1%) |
6 (2.3%) |
84 (3.2%) |
|
| C3 |
496 (17%) |
21 (8.1%) |
475 (18%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
2,659 (93%) |
199 (77%) |
2,460 (95%) |
|
| Oui |
204 (7.1%) |
61 (23%) |
143 (5.5%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
128 (4.5%) |
16 (6.2%) |
112 (4.3%) |
|
| Blood |
60 (2.1%) |
2 (0.8%) |
58 (2.2%) |
|
| Heterosexual |
1,335 (47%) |
53 (20%) |
1,282 (49%) |
|
| IDU |
141 (4.9%) |
4 (1.5%) |
137 (5.3%) |
|
| Mother to child transmission |
53 (1.9%) |
0 (0%) |
53 (2.0%) |
|
| MSM |
1,039 (36%) |
182 (70%) |
857 (33%) |
|
| Others |
13 (0.5%) |
1 (0.4%) |
12 (0.5%) |
|
| Unknown |
94 (3.3%) |
2 (0.8%) |
92 (3.5%) |
|
| Drug use |
|
|
|
|
| Current |
236 (8.6%) |
40 (16%) |
196 (7.8%) |
|
| None |
1,875 (68%) |
160 (63%) |
1,715 (69%) |
|
| Past |
261 (9.5%) |
20 (7.8%) |
241 (9.7%) |
|
| Sometimes |
147 (5.3%) |
28 (11%) |
119 (4.8%) |
|
| Substitution |
26 (0.9%) |
2 (0.8%) |
24 (1.0%) |
|
| Unknown |
207 (7.5%) |
5 (2.0%) |
202 (8.1%) |
|
| Baseline HIV RNA level (log10) |
4.80 (4.09, 5.42) |
4.87 (4.40, 5.66) |
4.77 (4.06, 5.40) |
<0.001 |
| Baseline CD4 count |
366 (190, 558) |
438 (317, 612) |
348 (175, 551) |
<0.001 |
Occitanie
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 353/3,626, i.e. 10%.

Cluster size and composition
Demographics by clustering status
| Characteristic |
Overall, N = 3,626 |
Clusters size ≥3, N = 353 |
Singletons, N = 3,273 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
898 (25%) |
10 (2.8%) |
888 (27%) |
|
| Male |
2,712 (75%) |
340 (96%) |
2,372 (72%) |
|
| Transgender M/F |
16 (0.4%) |
3 (0.8%) |
13 (0.4%) |
|
| Age |
49 (39, 59) |
42 (33, 50) |
50 (40, 59) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
97 (2.7%) |
14 (4.0%) |
83 (2.5%) |
|
| ≥25-<35 |
457 (13%) |
89 (25%) |
368 (11%) |
|
| ≥35-<45 |
814 (22%) |
115 (33%) |
699 (21%) |
|
| ≥45-<55 |
968 (27%) |
85 (24%) |
883 (27%) |
|
| ≥55-<80 |
1,245 (34%) |
48 (14%) |
1,197 (37%) |
|
| ≥80 |
45 (1.2%) |
2 (0.6%) |
43 (1.3%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
635 (19%) |
15 (4.4%) |
620 (20%) |
|
| WHO Americas |
94 (2.8%) |
7 (2.1%) |
87 (2.8%) |
|
| WHO Eastern Mediterranean |
106 (3.1%) |
5 (1.5%) |
101 (3.3%) |
|
| WHO Europe |
2,541 (74%) |
312 (92%) |
2,229 (73%) |
|
| WHO South-East Asia |
16 (0.5%) |
0 (0%) |
16 (0.5%) |
|
| WHO Western Pacific |
20 (0.6%) |
0 (0%) |
20 (0.7%) |
|
| HIV stage |
|
|
|
|
| A |
1 (<0.1%) |
0 (0%) |
1 (<0.1%) |
|
| A0 |
2 (<0.1%) |
1 (0.3%) |
1 (<0.1%) |
|
| A1 |
480 (13%) |
88 (25%) |
392 (12%) |
|
| A2 |
1,225 (34%) |
171 (48%) |
1,054 (32%) |
|
| A3 |
704 (19%) |
49 (14%) |
655 (20%) |
|
| B |
1 (<0.1%) |
0 (0%) |
1 (<0.1%) |
|
| B0 |
4 (0.1%) |
0 (0%) |
4 (0.1%) |
|
| B1 |
35 (1.0%) |
7 (2.0%) |
28 (0.9%) |
|
| B2 |
141 (3.9%) |
10 (2.8%) |
131 (4.0%) |
|
| B3 |
227 (6.3%) |
4 (1.1%) |
223 (6.8%) |
|
| C |
10 (0.3%) |
0 (0%) |
10 (0.3%) |
|
| C0 |
2 (<0.1%) |
0 (0%) |
2 (<0.1%) |
|
| C1 |
16 (0.4%) |
1 (0.3%) |
15 (0.5%) |
|
| C2 |
119 (3.3%) |
4 (1.1%) |
115 (3.5%) |
|
| C3 |
659 (18%) |
18 (5.1%) |
641 (20%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
3,194 (88%) |
254 (72%) |
2,940 (90%) |
|
| Oui |
432 (12%) |
99 (28%) |
333 (10%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
168 (4.6%) |
15 (4.2%) |
153 (4.7%) |
|
| Blood |
61 (1.7%) |
1 (0.3%) |
60 (1.8%) |
|
| Heterosexual |
1,203 (33%) |
30 (8.5%) |
1,173 (36%) |
|
| IDU |
199 (5.5%) |
4 (1.1%) |
195 (6.0%) |
|
| Mother to child transmission |
52 (1.4%) |
0 (0%) |
52 (1.6%) |
|
| MSM |
1,653 (46%) |
286 (81%) |
1,367 (42%) |
|
| Others |
29 (0.8%) |
3 (0.8%) |
26 (0.8%) |
|
| Unknown |
261 (7.2%) |
14 (4.0%) |
247 (7.5%) |
|
| Drug use |
|
|
|
|
| Current |
328 (11%) |
53 (17%) |
275 (9.8%) |
|
| None |
1,923 (62%) |
167 (53%) |
1,756 (63%) |
|
| Past |
351 (11%) |
25 (7.9%) |
326 (12%) |
|
| Sometimes |
296 (9.5%) |
60 (19%) |
236 (8.4%) |
|
| Substitution |
45 (1.4%) |
2 (0.6%) |
43 (1.5%) |
|
| Unknown |
174 (5.6%) |
10 (3.2%) |
164 (5.9%) |
|
| Baseline HIV RNA level (log10) |
4.92 (4.27, 5.59) |
5.08 (4.55, 5.80) |
4.89 (4.22, 5.57) |
<0.001 |
| Baseline CD4 count |
392 (202, 581) |
473 (334, 665) |
366 (178, 565) |
<0.001 |
Bretagne
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 50/1,256, i.e. 4%.

Cluster size and composition
Demographics by clustering status
| Characteristic |
Overall, N = 1,256 |
Clusters size ≥3, N = 50 |
Singletons, N = 1,206 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
428 (34%) |
4 (8.0%) |
424 (35%) |
|
| Male |
822 (65%) |
45 (90%) |
777 (64%) |
|
| Transgender F/M |
1 (<0.1%) |
0 (0%) |
1 (<0.1%) |
|
| Transgender M/F |
5 (0.4%) |
1 (2.0%) |
4 (0.3%) |
|
| Age |
52 (41, 60) |
48 (38, 59) |
52 (42, 60) |
0.2 |
| Age group |
|
|
|
0.5 |
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
38 (3.0%) |
1 (2.0%) |
37 (3.1%) |
|
| ≥25-<35 |
129 (10%) |
8 (16%) |
121 (10%) |
|
| ≥35-<45 |
245 (20%) |
13 (26%) |
232 (19%) |
|
| ≥45-<55 |
310 (25%) |
11 (22%) |
299 (25%) |
|
| ≥55-<80 |
518 (41%) |
17 (34%) |
501 (42%) |
|
| ≥80 |
16 (1.3%) |
0 (0%) |
16 (1.3%) |
|
| WHO region (origin) |
|
|
|
<0.001 |
| WHO Africa |
290 (24%) |
0 (0%) |
290 (25%) |
|
| WHO Americas |
33 (2.7%) |
0 (0%) |
33 (2.8%) |
|
| WHO Eastern Mediterranean |
9 (0.7%) |
0 (0%) |
9 (0.8%) |
|
| WHO Europe |
887 (72%) |
49 (100%) |
838 (71%) |
|
| WHO South-East Asia |
3 (0.2%) |
0 (0%) |
3 (0.3%) |
|
| WHO Western Pacific |
7 (0.6%) |
0 (0%) |
7 (0.6%) |
|
| HIV stage |
|
|
|
|
| A |
2 (0.2%) |
0 (0%) |
2 (0.2%) |
|
| A0 |
1 (<0.1%) |
0 (0%) |
1 (<0.1%) |
|
| A1 |
134 (11%) |
11 (22%) |
123 (10%) |
|
| A2 |
365 (29%) |
18 (36%) |
347 (29%) |
|
| A3 |
233 (19%) |
8 (16%) |
225 (19%) |
|
| B0 |
11 (0.9%) |
0 (0%) |
11 (0.9%) |
|
| B1 |
9 (0.7%) |
0 (0%) |
9 (0.7%) |
|
| B2 |
71 (5.7%) |
2 (4.0%) |
69 (5.7%) |
|
| B3 |
101 (8.0%) |
0 (0%) |
101 (8.4%) |
|
| C |
14 (1.1%) |
2 (4.0%) |
12 (1.0%) |
|
| C0 |
2 (0.2%) |
0 (0%) |
2 (0.2%) |
|
| C1 |
2 (0.2%) |
0 (0%) |
2 (0.2%) |
|
| C2 |
36 (2.9%) |
1 (2.0%) |
35 (2.9%) |
|
| C3 |
275 (22%) |
8 (16%) |
267 (22%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
1,183 (94%) |
40 (80%) |
1,143 (95%) |
|
| Oui |
73 (5.8%) |
10 (20%) |
63 (5.2%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
58 (4.6%) |
10 (20%) |
48 (4.0%) |
|
| Blood |
27 (2.1%) |
1 (2.0%) |
26 (2.2%) |
|
| Heterosexual |
563 (45%) |
5 (10%) |
558 (46%) |
|
| IDU |
72 (5.7%) |
3 (6.0%) |
69 (5.7%) |
|
| Mother to child transmission |
27 (2.1%) |
0 (0%) |
27 (2.2%) |
|
| MSM |
438 (35%) |
30 (60%) |
408 (34%) |
|
| Others |
15 (1.2%) |
0 (0%) |
15 (1.2%) |
|
| Unknown |
56 (4.5%) |
1 (2.0%) |
55 (4.6%) |
|
| Drug use |
|
|
|
0.032 |
| Current |
90 (9.0%) |
8 (20%) |
82 (8.6%) |
|
| None |
425 (43%) |
19 (46%) |
406 (43%) |
|
| Past |
74 (7.4%) |
0 (0%) |
74 (7.8%) |
|
| Sometimes |
23 (2.3%) |
1 (2.4%) |
22 (2.3%) |
|
| Substitution |
22 (2.2%) |
2 (4.9%) |
20 (2.1%) |
|
| Unknown |
361 (36%) |
11 (27%) |
350 (37%) |
|
| Baseline HIV RNA level (log10) |
4.87 (4.14, 5.48) |
5.07 (4.16, 5.62) |
4.86 (4.14, 5.48) |
0.5 |
| Baseline CD4 count |
353 (180, 547) |
423 (253, 595) |
351 (175, 543) |
0.2 |
Provence-Alpes-Côte-d’Azur
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 256/2,787, i.e. 9%.

Cluster size and composition
Demographics by clustering status
| Characteristic |
Overall, N = 2,787 |
Clusters size ≥3, N = 256 |
Singletons, N = 2,531 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
728 (26%) |
18 (7.0%) |
710 (28%) |
|
| Male |
2,005 (72%) |
234 (91%) |
1,771 (70%) |
|
| Transgender M/F |
54 (1.9%) |
4 (1.6%) |
50 (2.0%) |
|
| Age |
52 (41, 60) |
42 (34, 52) |
53 (42, 60) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
59 (2.1%) |
16 (6.3%) |
43 (1.7%) |
|
| ≥25-<35 |
307 (11%) |
53 (21%) |
254 (10%) |
|
| ≥35-<45 |
545 (20%) |
79 (31%) |
466 (18%) |
|
| ≥45-<55 |
671 (24%) |
55 (21%) |
616 (24%) |
|
| ≥55-<80 |
1,179 (42%) |
52 (20%) |
1,127 (45%) |
|
| ≥80 |
26 (0.9%) |
1 (0.4%) |
25 (1.0%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
308 (16%) |
8 (4.0%) |
300 (17%) |
|
| WHO Americas |
118 (6.1%) |
7 (3.5%) |
111 (6.4%) |
|
| WHO Eastern Mediterranean |
89 (4.6%) |
5 (2.5%) |
84 (4.9%) |
|
| WHO Europe |
1,382 (72%) |
178 (89%) |
1,204 (70%) |
|
| WHO South-East Asia |
7 (0.4%) |
1 (0.5%) |
6 (0.3%) |
|
| WHO Western Pacific |
18 (0.9%) |
0 (0%) |
18 (1.0%) |
|
| HIV stage |
|
|
|
|
| A |
2 (<0.1%) |
0 (0%) |
2 (<0.1%) |
|
| A0 |
20 (0.7%) |
2 (0.8%) |
18 (0.7%) |
|
| A1 |
390 (14%) |
83 (32%) |
307 (12%) |
|
| A2 |
983 (35%) |
126 (49%) |
857 (34%) |
|
| A3 |
442 (16%) |
20 (7.8%) |
422 (17%) |
|
| B0 |
2 (<0.1%) |
0 (0%) |
2 (<0.1%) |
|
| B1 |
23 (0.8%) |
2 (0.8%) |
21 (0.8%) |
|
| B2 |
118 (4.2%) |
5 (2.0%) |
113 (4.5%) |
|
| B3 |
187 (6.7%) |
3 (1.2%) |
184 (7.3%) |
|
| C |
1 (<0.1%) |
0 (0%) |
1 (<0.1%) |
|
| C0 |
3 (0.1%) |
0 (0%) |
3 (0.1%) |
|
| C1 |
22 (0.8%) |
0 (0%) |
22 (0.9%) |
|
| C2 |
107 (3.8%) |
6 (2.3%) |
101 (4.0%) |
|
| C3 |
487 (17%) |
9 (3.5%) |
478 (19%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
2,555 (92%) |
205 (80%) |
2,350 (93%) |
|
| Oui |
232 (8.3%) |
51 (20%) |
181 (7.2%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
123 (4.4%) |
18 (7.0%) |
105 (4.1%) |
|
| Blood |
44 (1.6%) |
0 (0%) |
44 (1.7%) |
|
| Heterosexual |
992 (36%) |
46 (18%) |
946 (37%) |
|
| IDU |
392 (14%) |
11 (4.3%) |
381 (15%) |
|
| Mother to child transmission |
51 (1.8%) |
0 (0%) |
51 (2.0%) |
|
| MSM |
1,109 (40%) |
179 (70%) |
930 (37%) |
|
| Others |
11 (0.4%) |
0 (0%) |
11 (0.4%) |
|
| Unknown |
65 (2.3%) |
2 (0.8%) |
63 (2.5%) |
|
| Drug use |
|
|
|
|
| Current |
300 (11%) |
46 (18%) |
254 (10%) |
|
| None |
788 (29%) |
68 (27%) |
720 (29%) |
|
| Past |
335 (12%) |
38 (15%) |
297 (12%) |
|
| Sometimes |
33 (1.2%) |
3 (1.2%) |
30 (1.2%) |
|
| Substitution |
55 (2.0%) |
0 (0%) |
55 (2.2%) |
|
| Unknown |
1,215 (45%) |
97 (38%) |
1,118 (45%) |
|
| Baseline HIV RNA level (log10) |
4.81 (4.08, 5.46) |
4.90 (4.21, 5.43) |
4.81 (4.04, 5.46) |
0.082 |
| Baseline CD4 count |
410 (247, 591) |
510 (357, 696) |
390 (221, 567) |
<0.001 |
Normandie
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 28/690, i.e. 4%.

Cluster size and composition
Demographics by clustering status
| Characteristic |
Overall, N = 690 |
Clusters size ≥3, N = 28 |
Singletons, N = 662 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
242 (35%) |
1 (3.6%) |
241 (36%) |
|
| Male |
431 (62%) |
27 (96%) |
404 (61%) |
|
| Transgender F/M |
1 (0.1%) |
0 (0%) |
1 (0.2%) |
|
| Transgender M/F |
16 (2.3%) |
0 (0%) |
16 (2.4%) |
|
| Age |
49 (38, 58) |
48 (33, 53) |
49 (38, 58) |
0.067 |
| Age group |
|
|
|
0.011 |
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
21 (3.0%) |
4 (14%) |
17 (2.6%) |
|
| ≥25-<35 |
107 (16%) |
4 (14%) |
103 (16%) |
|
| ≥35-<45 |
148 (21%) |
5 (18%) |
143 (22%) |
|
| ≥45-<55 |
174 (25%) |
11 (39%) |
163 (25%) |
|
| ≥55-<80 |
233 (34%) |
4 (14%) |
229 (35%) |
|
| ≥80 |
7 (1.0%) |
0 (0%) |
7 (1.1%) |
|
| WHO region (origin) |
|
|
|
0.032 |
| WHO Africa |
206 (31%) |
2 (7.4%) |
204 (32%) |
|
| WHO Americas |
36 (5.4%) |
0 (0%) |
36 (5.6%) |
|
| WHO Eastern Mediterranean |
6 (0.9%) |
0 (0%) |
6 (0.9%) |
|
| WHO Europe |
419 (62%) |
25 (93%) |
394 (61%) |
|
| WHO South-East Asia |
3 (0.4%) |
0 (0%) |
3 (0.5%) |
|
| WHO Western Pacific |
1 (0.1%) |
0 (0%) |
1 (0.2%) |
|
| HIV stage |
|
|
|
|
| A1 |
102 (15%) |
11 (39%) |
91 (14%) |
|
| A2 |
219 (32%) |
14 (50%) |
205 (31%) |
|
| A3 |
102 (15%) |
1 (3.6%) |
101 (15%) |
|
| B |
1 (0.1%) |
0 (0%) |
1 (0.2%) |
|
| B1 |
9 (1.3%) |
0 (0%) |
9 (1.4%) |
|
| B2 |
39 (5.7%) |
1 (3.6%) |
38 (5.7%) |
|
| B3 |
52 (7.5%) |
0 (0%) |
52 (7.9%) |
|
| C |
1 (0.1%) |
0 (0%) |
1 (0.2%) |
|
| C0 |
1 (0.1%) |
0 (0%) |
1 (0.2%) |
|
| C1 |
2 (0.3%) |
0 (0%) |
2 (0.3%) |
|
| C2 |
23 (3.3%) |
0 (0%) |
23 (3.5%) |
|
| C3 |
139 (20%) |
1 (3.6%) |
138 (21%) |
|
| Primo-infection |
|
|
|
0.002 |
| Non |
578 (84%) |
17 (61%) |
561 (85%) |
|
| Oui |
112 (16%) |
11 (39%) |
101 (15%) |
|
| Transmission risk |
|
|
|
0.2 |
| Bisexual |
45 (6.5%) |
5 (18%) |
40 (6.0%) |
|
| Blood |
11 (1.6%) |
0 (0%) |
11 (1.7%) |
|
| Heterosexual |
356 (52%) |
9 (32%) |
347 (52%) |
|
| IDU |
39 (5.7%) |
1 (3.6%) |
38 (5.7%) |
|
| Mother to child transmission |
8 (1.2%) |
0 (0%) |
8 (1.2%) |
|
| MSM |
203 (29%) |
12 (43%) |
191 (29%) |
|
| Others |
6 (0.9%) |
0 (0%) |
6 (0.9%) |
|
| Unknown |
22 (3.2%) |
1 (3.6%) |
21 (3.2%) |
|
| Drug use |
|
|
|
0.029 |
| Current |
51 (11%) |
5 (22%) |
46 (10%) |
|
| None |
309 (65%) |
11 (48%) |
298 (65%) |
|
| Past |
47 (9.8%) |
6 (26%) |
41 (9.0%) |
|
| Sometimes |
18 (3.8%) |
1 (4.3%) |
17 (3.7%) |
|
| Substitution |
21 (4.4%) |
0 (0%) |
21 (4.6%) |
|
| Unknown |
33 (6.9%) |
0 (0%) |
33 (7.2%) |
|
| Baseline HIV RNA level (log10) |
4.78 (3.88, 5.53) |
5.34 (4.44, 6.16) |
4.76 (3.84, 5.51) |
0.011 |
| Baseline CD4 count |
353 (180, 574) |
503 (361, 648) |
340 (175, 569) |
0.005 |
Guadeloupe
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 37/645, i.e. 6%.

Cluster size and composition
Demographics by clustering status
| Characteristic |
Overall, N = 645 |
Clusters size ≥3, N = 37 |
Singletons, N = 608 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
240 (37%) |
2 (5.4%) |
238 (39%) |
|
| Male |
405 (63%) |
35 (95%) |
370 (61%) |
|
| Age |
50 (38, 60) |
34 (28, 45) |
50 (40, 60) |
<0.001 |
| Age group |
|
|
|
<0.001 |
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
29 (4.5%) |
5 (14%) |
24 (3.9%) |
|
| ≥25-<35 |
100 (16%) |
16 (43%) |
84 (14%) |
|
| ≥35-<45 |
110 (17%) |
5 (14%) |
105 (17%) |
|
| ≥45-<55 |
169 (26%) |
7 (19%) |
162 (27%) |
|
| ≥55-<80 |
223 (35%) |
4 (11%) |
219 (36%) |
|
| ≥80 |
14 (2.2%) |
0 (0%) |
14 (2.3%) |
|
| WHO region (origin) |
|
|
|
0.011 |
| WHO Africa |
4 (0.6%) |
0 (0%) |
4 (0.7%) |
|
| WHO Americas |
232 (36%) |
4 (11%) |
228 (38%) |
|
| WHO Eastern Mediterranean |
2 (0.3%) |
0 (0%) |
2 (0.3%) |
|
| WHO Europe |
399 (62%) |
33 (89%) |
366 (61%) |
|
| WHO South-East Asia |
1 (0.2%) |
0 (0%) |
1 (0.2%) |
|
| WHO Western Pacific |
1 (0.2%) |
0 (0%) |
1 (0.2%) |
|
| HIV stage |
|
|
|
|
| A |
2 (0.3%) |
1 (2.7%) |
1 (0.2%) |
|
| A0 |
1 (0.2%) |
0 (0%) |
1 (0.2%) |
|
| A1 |
66 (10%) |
9 (24%) |
57 (9.4%) |
|
| A2 |
204 (32%) |
19 (51%) |
185 (30%) |
|
| A3 |
114 (18%) |
2 (5.4%) |
112 (18%) |
|
| B1 |
6 (0.9%) |
0 (0%) |
6 (1.0%) |
|
| B2 |
17 (2.6%) |
0 (0%) |
17 (2.8%) |
|
| B3 |
38 (5.9%) |
2 (5.4%) |
36 (5.9%) |
|
| C |
1 (0.2%) |
0 (0%) |
1 (0.2%) |
|
| C1 |
3 (0.5%) |
1 (2.7%) |
2 (0.3%) |
|
| C2 |
12 (1.9%) |
0 (0%) |
12 (2.0%) |
|
| C3 |
181 (28%) |
3 (8.1%) |
178 (29%) |
|
| Primo-infection |
|
|
|
0.004 |
| Non |
616 (96%) |
31 (84%) |
585 (96%) |
|
| Oui |
29 (4.5%) |
6 (16%) |
23 (3.8%) |
|
| Transmission risk |
|
|
|
<0.001 |
| Bisexual |
41 (6.4%) |
4 (11%) |
37 (6.1%) |
|
| Blood |
5 (0.8%) |
0 (0%) |
5 (0.8%) |
|
| Heterosexual |
470 (73%) |
15 (41%) |
455 (75%) |
|
| IDU |
7 (1.1%) |
0 (0%) |
7 (1.2%) |
|
| Mother to child transmission |
6 (0.9%) |
0 (0%) |
6 (1.0%) |
|
| MSM |
101 (16%) |
17 (46%) |
84 (14%) |
|
| Others |
1 (0.2%) |
0 (0%) |
1 (0.2%) |
|
| Unknown |
14 (2.2%) |
1 (2.7%) |
13 (2.1%) |
|
| Drug use |
|
|
|
0.065 |
| Current |
44 (7.8%) |
6 (19%) |
38 (7.1%) |
|
| None |
425 (75%) |
23 (72%) |
402 (75%) |
|
| Past |
45 (8.0%) |
0 (0%) |
45 (8.4%) |
|
| Sometimes |
17 (3.0%) |
2 (6.3%) |
15 (2.8%) |
|
| Substitution |
2 (0.4%) |
0 (0%) |
2 (0.4%) |
|
| Unknown |
32 (5.7%) |
1 (3.1%) |
31 (5.8%) |
|
| Baseline HIV RNA level (log10) |
4.67 (4.07, 5.16) |
4.64 (4.16, 4.95) |
4.67 (4.07, 5.18) |
0.8 |
| Baseline CD4 count |
332 (149, 494) |
394 (301, 557) |
327 (140, 491) |
0.052 |
Auvergne-Rhône-Alpes
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 8/303, i.e. 3%.

Cluster size and composition
Demographics by clustering status
| Characteristic |
Overall, N = 303 |
Clusters size ≥3, N = 8 |
Singletons, N = 295 |
p-value |
| sex |
|
|
|
0.082 |
| Female |
98 (32%) |
0 (0%) |
98 (33%) |
|
| Male |
204 (67%) |
8 (100%) |
196 (66%) |
|
| Transgender M/F |
1 (0.3%) |
0 (0%) |
1 (0.3%) |
|
| Age |
49 (38, 58) |
52 (44, 54) |
48 (38, 58) |
0.7 |
| Age group |
|
|
|
0.6 |
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
4 (1.3%) |
0 (0%) |
4 (1.4%) |
|
| ≥25-<35 |
47 (16%) |
0 (0%) |
47 (16%) |
|
| ≥35-<45 |
75 (25%) |
2 (25%) |
73 (25%) |
|
| ≥45-<55 |
77 (25%) |
4 (50%) |
73 (25%) |
|
| ≥55-<80 |
95 (31%) |
2 (25%) |
93 (32%) |
|
| ≥80 |
5 (1.7%) |
0 (0%) |
5 (1.7%) |
|
| WHO region (origin) |
|
|
|
0.5 |
| WHO Africa |
65 (22%) |
0 (0%) |
65 (23%) |
|
| WHO Americas |
9 (3.1%) |
0 (0%) |
9 (3.2%) |
|
| WHO Eastern Mediterranean |
5 (1.7%) |
0 (0%) |
5 (1.8%) |
|
| WHO Europe |
209 (72%) |
8 (100%) |
201 (71%) |
|
| WHO South-East Asia |
1 (0.3%) |
0 (0%) |
1 (0.4%) |
|
| WHO Western Pacific |
2 (0.7%) |
0 (0%) |
2 (0.7%) |
|
| HIV stage |
|
|
|
0.2 |
| A1 |
48 (16%) |
4 (50%) |
44 (15%) |
|
| A2 |
97 (32%) |
4 (50%) |
93 (32%) |
|
| A3 |
52 (17%) |
0 (0%) |
52 (18%) |
|
| B1 |
2 (0.7%) |
0 (0%) |
2 (0.7%) |
|
| B2 |
15 (5.0%) |
0 (0%) |
15 (5.1%) |
|
| B3 |
24 (7.9%) |
0 (0%) |
24 (8.1%) |
|
| C1 |
3 (1.0%) |
0 (0%) |
3 (1.0%) |
|
| C2 |
6 (2.0%) |
0 (0%) |
6 (2.0%) |
|
| C3 |
56 (18%) |
0 (0%) |
56 (19%) |
|
| Primo-infection |
|
|
|
0.12 |
| Non |
255 (84%) |
5 (63%) |
250 (85%) |
|
| Oui |
48 (16%) |
3 (38%) |
45 (15%) |
|
| Transmission risk |
|
|
|
0.090 |
| Bisexual |
24 (7.9%) |
2 (25%) |
22 (7.5%) |
|
| Blood |
6 (2.0%) |
0 (0%) |
6 (2.0%) |
|
| Heterosexual |
127 (42%) |
0 (0%) |
127 (43%) |
|
| IDU |
8 (2.6%) |
0 (0%) |
8 (2.7%) |
|
| Mother to child transmission |
9 (3.0%) |
0 (0%) |
9 (3.1%) |
|
| MSM |
117 (39%) |
6 (75%) |
111 (38%) |
|
| Others |
1 (0.3%) |
0 (0%) |
1 (0.3%) |
|
| Unknown |
11 (3.6%) |
0 (0%) |
11 (3.7%) |
|
| Drug use |
|
|
|
0.7 |
| Current |
40 (14%) |
2 (25%) |
38 (14%) |
|
| None |
190 (66%) |
6 (75%) |
184 (66%) |
|
| Past |
36 (13%) |
0 (0%) |
36 (13%) |
|
| Sometimes |
8 (2.8%) |
0 (0%) |
8 (2.9%) |
|
| Substitution |
4 (1.4%) |
0 (0%) |
4 (1.4%) |
|
| Unknown |
10 (3.5%) |
0 (0%) |
10 (3.6%) |
|
| Baseline HIV RNA level (log10) |
4.65 (3.98, 5.26) |
5.26 (4.41, 6.03) |
4.64 (3.97, 5.25) |
0.2 |
| Baseline CD4 count |
442 (271, 638) |
601 (538, 657) |
436 (269, 634) |
0.2 |
Martinique
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 94/922, i.e. 10%.

Cluster size and composition
Demographics by clustering status
| Characteristic |
Overall, N = 922 |
Clusters size ≥3, N = 94 |
Singletons, N = 828 |
p-value |
| sex |
|
|
|
0.4 |
| Female |
318 (34%) |
27 (29%) |
291 (35%) |
|
| Male |
599 (65%) |
67 (71%) |
532 (64%) |
|
| Transgender M/F |
5 (0.5%) |
0 (0%) |
5 (0.6%) |
|
| Age |
53 (40, 63) |
37 (30, 52) |
55 (42, 63) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
32 (3.5%) |
9 (9.6%) |
23 (2.8%) |
|
| ≥25-<35 |
123 (13%) |
33 (35%) |
90 (11%) |
|
| ≥35-<45 |
145 (16%) |
17 (18%) |
128 (15%) |
|
| ≥45-<55 |
182 (20%) |
14 (15%) |
168 (20%) |
|
| ≥55-<80 |
413 (45%) |
21 (22%) |
392 (47%) |
|
| ≥80 |
27 (2.9%) |
0 (0%) |
27 (3.3%) |
|
| WHO region (origin) |
|
|
|
0.013 |
| WHO Africa |
13 (1.5%) |
0 (0%) |
13 (1.6%) |
|
| WHO Americas |
121 (14%) |
5 (5.6%) |
116 (15%) |
|
| WHO Eastern Mediterranean |
2 (0.2%) |
1 (1.1%) |
1 (0.1%) |
|
| WHO Europe |
751 (85%) |
84 (93%) |
667 (84%) |
|
| HIV stage |
|
|
|
|
| A0 |
1 (0.1%) |
0 (0%) |
1 (0.1%) |
|
| A1 |
96 (10%) |
20 (21%) |
76 (9.2%) |
|
| A2 |
277 (30%) |
39 (41%) |
238 (29%) |
|
| A3 |
167 (18%) |
18 (19%) |
149 (18%) |
|
| B1 |
5 (0.5%) |
0 (0%) |
5 (0.6%) |
|
| B2 |
39 (4.2%) |
3 (3.2%) |
36 (4.3%) |
|
| B3 |
63 (6.8%) |
2 (2.1%) |
61 (7.4%) |
|
| C0 |
1 (0.1%) |
0 (0%) |
1 (0.1%) |
|
| C1 |
2 (0.2%) |
2 (2.1%) |
0 (0%) |
|
| C2 |
19 (2.1%) |
1 (1.1%) |
18 (2.2%) |
|
| C3 |
252 (27%) |
9 (9.6%) |
243 (29%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
851 (92%) |
77 (82%) |
774 (93%) |
|
| Oui |
71 (7.7%) |
17 (18%) |
54 (6.5%) |
|
| Transmission risk |
|
|
|
0.041 |
| Bisexual |
126 (14%) |
22 (23%) |
104 (13%) |
|
| Blood |
9 (1.0%) |
1 (1.1%) |
8 (1.0%) |
|
| Heterosexual |
588 (64%) |
47 (50%) |
541 (65%) |
|
| IDU |
14 (1.5%) |
1 (1.1%) |
13 (1.6%) |
|
| Mother to child transmission |
3 (0.3%) |
0 (0%) |
3 (0.4%) |
|
| MSM |
169 (18%) |
23 (24%) |
146 (18%) |
|
| Others |
1 (0.1%) |
0 (0%) |
1 (0.1%) |
|
| Unknown |
12 (1.3%) |
0 (0%) |
12 (1.4%) |
|
| Drug use |
|
|
|
0.041 |
| Current |
108 (13%) |
18 (21%) |
90 (12%) |
|
| None |
595 (70%) |
50 (59%) |
545 (71%) |
|
| Past |
124 (14%) |
13 (15%) |
111 (14%) |
|
| Sometimes |
16 (1.9%) |
4 (4.7%) |
12 (1.6%) |
|
| Substitution |
4 (0.5%) |
0 (0%) |
4 (0.5%) |
|
| Unknown |
9 (1.1%) |
0 (0%) |
9 (1.2%) |
|
| Baseline HIV RNA level (log10) |
4.53 (3.94, 5.10) |
4.36 (4.04, 4.94) |
4.54 (3.93, 5.12) |
0.3 |
| Baseline CD4 count |
393 (208, 571) |
441 (320, 626) |
385 (191, 562) |
0.005 |